NCT03490786已完成1 期
A Dose Escalating Study to Assess the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Lingual Application of GT-001 in Subjects With Obesity.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Demonstrate safe doses of PGT-001 for reduction of body weight in obese volunteers.
研究概览
简要总结
Dose escalation study of GT-001
详细描述
This is a dose-escalation design trial. Twelve evaluable subjects (n=12) with BMIs of 30 to 40 kg/m2 will receive a single dose of placebo followed by study drug applied directly to the surface of the tongue mucosa with a disposable pipette followed by a one-day washout. A total of seven (7) doses will escalate to a dose of 2.5 mg.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult participants with obesity class I and II (BMI 30-40 kg/m2)
- •Willing and able to provide written informed consent after reviewing the design and risks of the study and prior to completing any study-related procedure
- •Willing and able to understand and comply with all study procedures and requirements.
- •Women must have a predictable menstrual cycle and taking either monophasic oral contraceptives, or transdermal (Ortho Evra and Evra) at least one month prior to the study.
- •Alternatively, post-menopausal women (defined as period of spontaneous amenorrhea for more than 1 year), and bilateral oophorectomized women are allowed into the study.
- •Must be able to complete the Weight Efficacy Life-Style Questionnaire (WEL).
- •Systolic blood pressure 100-160 mmHg at the time of screening.
- •Stable and compliant treatment with oral medications for at least 4 weeks prior to screening.
- •Women of child bearing potential (WOCBP) and males must agree to use at least two forms of contraception, of which one includes a barrier method (male condom) by the male partner, during study participation and continued for at least 90 days after the conclusion of the final dose.
- •In addition, sperm donations by male subjects are not permitted during the subject's participation in the research study and for at least 90 days after the conclusion of the final dose. This criterion may be waived for male subjects who have undergone a vasectomy at least 6 months prior to screening.
- •Willing and able to abstain from drugs, , and tobacco during study participation.
- •Must have abstained from alcohol use for 48 hours prior to study day 1 through the duration of the study
- •Must have abstained from any tobacco- or nicotine-containing products (e.g., cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to study day
- •History of stable weight for at least 3 months prior to study entry.
排除标准
- •Known hypersensitivity or allergy to Peptide YY, Pancreatic polypeptide (PP), other similar polypeptides or related compounds
- •Known mutation to PYY or Y2 receptor gene (i.e., Pima Indians)
- •Any medical condition for which modification of the medication that cannot be performed either safely or feasibly. Chronic diseases including metabolic, psychiatric, cardiovascular, endocrine, etc. for which the participant is not stable for 60 days prior to study initiation
- •Female subjects who are pregnant or breast-feeding
- •Female subjects of child bearing potential who are not on oral contraceptives or using biphasic or triphasic oral contraceptives
- •Post-menopausal women who have not had a period of spontaneous amenorrhea for more than 1 year Unstable psychological or behavior profile (e.g., anxiety, depression)
- •Subjects with fasting glucose levels greater than 125 mg/dl.
- •Type I or Type II diabetes
- •Poor dentition or oral pathology
- •Unable or unwilling to give written informed consent.
- •Temperature > 38°C (oral or equivalent)
- •Sepsis or active infection requiring IV antimicrobial treatment
- •Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (not including restrictive mitral filling patterns)
- •Major neurologic event, including cerebrovascular events within 60 days prior to study initiation
- •Significant pulmonary disease (e.g., history of oral daily steroid dependency, history of CO2 retention or need for intubation for acute exacerbation, or currently receiving IV steroids)
- •Known hepatic impairment as indicated by any of the following:
- •Total bilirubin > 3 mg/dl
- •Albumin < 2.8 mg/dl, with other signs or symptoms of hepatic dysfunction
- •Increased ammonia levels, if performed, with other signs or symptoms of hepatic dysfunction
- •Any organ transplant recipient or currently listed (anticipated in the next 60 days) for transplant
- •Major surgery within 30 days prior to study initiation
- •Positive screen for Hepatitis B (HbsAg, Hepatitis B Surface Antigen), Hepatitis C (anti-HCV, Hepatitis C Antibody), or HIV (anti-HIV 1/2)
- •Received an investigational intervention within 30 days prior to study initiation, or have received PYY3-36, GLP-1 agonists, insulin or DPP-IV inhibitors in a previous clinical trial.
- •Consumption of alcohol within 48 hours prior to study day1 and through study day 15 or early termination
- •Use of any tobacco- or nicotine-containing products (e.g., cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months
- •A positive urine drug screen for ethanol, cotinine, cocaine, THC, barbiturates, amphetamines, benzodiazepines, and/or opiates
- •A history of difficulty with donating blood, or having donated blood or blood products within 45 days prior to study initiation
- •Use of weight loss drugs Orlistat (Alli or Xenical), Qsymia, Phentermine, Contrave, Lorcaserin, liraglutide, topiramate or exenatide within the last six months.
- •Concurrent use of antihistamines
- •Any condition that, in the opinion of the Investigator or Medical Monitor, would render the subject unsuitable for participation in the study
- •Unable to consume the test meal
研究组 & 干预措施
Dose escalation
Experimental
Single arm dose escalation.
干预措施: GT-001 (Drug)
结局指标
主要结局
Demonstrate safe doses of PGT-001 for reduction of body weight in obese volunteers.
时间窗: approximately two weeks
Measures of the safety and tolerability of GT-001 include documentation of adverse events and changes (compared to baseline) in vital signs, physical examination, and laboratory tests.
次要结局
- Dose-relationship of adverse events(approximately two weeks)
- Dose relationship to peak plasma concentration of GT-001(Approximately two weeks)
- Dose relationship to hunger and satiety(approximately two weeks)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Dose-Escalation Study to Evaluate the Safety and Tolerability of SCH 717454 in Combination with Different Treatment Regimens in Subjects with Advanced Solid Tumors (Phase 1b/2; Protocol No. P04722) - N/AColorectal Adenocarcinoma, Non-small Cell Lung Cancer, Gastric Adenocarcinoma, Her2+ Breast Cancer, Renal Cell Cancer, Pancreatic AdenocarcinomaMedDRA version: 12.0 Level: LLT Classification code 10001150 Term: Adenocarcinoma gastricMedDRA version: 12.0 Level: LLT Classification code 10065430 Term: HER-2 positive breast cancerMedDRA version: 12.0 Level: LLT Classification code 10038407 Term: Renal cell cancerMedDRA version: 12.0 Level: LLT Classification code 10051971 Term: Pancreatic adenocarcinomaMedDRA version: 12.0 Level: PT Classification code 10052360 Term: <Manually entered code. Term in E.1.1>MedDRA version: 12.0 Level: PT Classification code 10061873 Term: <Manually entered code. Term in E.1.1>EUCTR2009-011101-16-GBSchering-Plough Research Institute, A Division of Schering Corporation250
已完成
1 期
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic MalignanciesNon-Hodgkin's LymphomaPeripheral T-Cell LymphomaHodgkin's LymphomaChronic Lymphocytic LeukemiaNCT01767766TG Therapeutics, Inc.90
已完成
不适用
Dose-escalation study to evaluate safety and gastrointestinal tolerability of allulose in subjects compared to placeboHealthy subjectsDRKS00017848Pfeifer & Langen GmbH & Co. KG49
招募中
1 期
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic MalignanciesNon Small Cell Lung CancerAdvanced Solid TumorHematologic MalignancyNCT06484816Shenzhen TargetRx, Inc.90
已完成
1 期
Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered IntravenouslyHealthy SubjectsNCT00783341Wyeth is now a wholly owned subsidiary of Pfizer25